Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim A Papp

Showing results (101-110 of 219) with videos related to

Pageof 22
Sort By:
Journal of the American Academy of Dermatology|February 5, 2005
Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccinationKim A Papp, Kristine Breuer, Michael Meurer, et al.
The Journal of Investigative Dermatology|October 21, 2011
A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasisKenneth B Gordon, Richard G Langley, Alice B Gottlieb, et al.
Dermatology and Therapy|April 25, 2025
Canadian Consensus Guidelines for the Management of Atopic Dermatitis with Topical TherapiesMelinda J Gooderham, H Chih-Ho Hong, Charles Lynde, et al.
Journal of Drugs in Dermatology : JDD|March 8, 2012
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-upKristian Reich, Kim A Papp, Christopher E M Griffiths, et al.
Journal of Cutaneous Medicine and Surgery|December 15, 2022
Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 PathwayWei Jing Loo, Irina Turchin, Vimal H Prajapati, et al.
Journal of the American Academy of Dermatology|August 29, 2013
Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinicsPhilip J Mease, Dafna D Gladman, Kim A Papp, et al.
The Journal of Dermatology|July 18, 2017
Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trialMasatoshi Abe, Chikako Nishigori, Hideshi Torii, et al.
Dermatology and Therapy|April 20, 2025
Canadian Consensus Guidelines for the Management of VitiligoVimal H Prajapati, Harvey Lui, Yvette Miller-Monthrope, et al.
Journal of the American Academy of Dermatology|February 5, 2005
Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year studyKim A Papp, Thomas Werfel, Regina Fölster-Holst, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 10, 2025
Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasisJoseph F Merola, Lyn Guenther, Charles Lynde, et al.
Pageof 22

Showing results (101-110 of 219) with videos related to

Sort By:
Pageof 22
Journal of the American Academy of Dermatology|February 5, 2005
Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccinationKim A Papp, Kristine Breuer, Michael Meurer, et al.
The Journal of Investigative Dermatology|October 21, 2011
A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasisKenneth B Gordon, Richard G Langley, Alice B Gottlieb, et al.
Dermatology and Therapy|April 25, 2025
Canadian Consensus Guidelines for the Management of Atopic Dermatitis with Topical TherapiesMelinda J Gooderham, H Chih-Ho Hong, Charles Lynde, et al.
Journal of Drugs in Dermatology : JDD|March 8, 2012
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-upKristian Reich, Kim A Papp, Christopher E M Griffiths, et al.
Journal of Cutaneous Medicine and Surgery|December 15, 2022
Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 PathwayWei Jing Loo, Irina Turchin, Vimal H Prajapati, et al.
Journal of the American Academy of Dermatology|August 29, 2013
Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinicsPhilip J Mease, Dafna D Gladman, Kim A Papp, et al.
The Journal of Dermatology|July 18, 2017
Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trialMasatoshi Abe, Chikako Nishigori, Hideshi Torii, et al.
Dermatology and Therapy|April 20, 2025
Canadian Consensus Guidelines for the Management of VitiligoVimal H Prajapati, Harvey Lui, Yvette Miller-Monthrope, et al.
Journal of the American Academy of Dermatology|February 5, 2005
Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year studyKim A Papp, Thomas Werfel, Regina Fölster-Holst, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 10, 2025
Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasisJoseph F Merola, Lyn Guenther, Charles Lynde, et al.
Pageof 22